A*STAR Singapore Immunology Network (A*STAR SIgN)

Research suggests monitoring individuals previously infected with Zika virus for chronic skin diseases caused by overactive T cells.

Researchers identify predictive immune ‘signatures’ in liver cancer patients that can help tailor and improve the success rates of combined immunotherapy and radiotherapy.

While the new Omicron XBB COVID-19 subvariant deftly dodges immune defences even in vaccinated individuals, researchers find that mixed mRNA vaccines may offer a vital boost of protection.

From molecular methods to advanced optics, scientists are combining techniques and expertise from diverse disciplines to transform skin health research and fortify the body’s outermost barrier.

A*STAR researchers tackle the challenge of creating therapeutic antibodies that effectively kill tumours and are also easily scalable in manufacturing settings.

Through close collaborations across scientific disciplines, A*STAR drives new discoveries in neurometabolism and its potential therapeutic applications.

Researchers discover key differences in the skin’s natural flora between healthy adults and those with genetic dry skin diseases.

Researchers discover that circadian rhythms control immune responses and may affect how our skin’s immune system responds to allergies.

Researchers develop a protocol to boost the effectiveness of and reduce the risk of potential side effects for T cell cancer therapies.

A novel tissue-profiling approach provides new insights into the mechanisms of fatal COVID-19 by analysing
different molecules and cell populations within organs.

New associations between COVID-19 and immune responses in cancer patients reveal potential inroads to fighting tumours.

Inactivated COVID-19 vaccines could be an equally potent alternative for people with allergic sensitivities to mRNA-based vaccines.